Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Complete remission with incomplete count recovery (CRi) prior to allogeneic HCT for acute myeloid leukaemia is associated with a high non-relapse mortality.

Innes AJ, Woolley P, Szydlo RM, Lozano S, Fernando F, Bansal D, Palanicawandar R, Milojkovic D, May PC, Nadal-Melsio E, Yebra-Fernandez E, Olavarria E, Apperley JF, Pavlů J.

Leukemia. 2019 Sep 2. doi: 10.1038/s41375-019-0572-z. [Epub ahead of print] No abstract available.

PMID:
31477799
2.

The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients.

Nesr G, Claudiani S, Khorashad J, Apperley J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 22:1-2. doi: 10.1080/10428194.2019.1627536. [Epub ahead of print] No abstract available.

PMID:
31232126
3.

De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Rothwell K, Pocock C, Byrne J, de Lavallade H, Osborne W, Robinson L, O'Brien SG, Read L, Foroni L, Copland M.

Lancet Haematol. 2019 Jul;6(7):e375-e383. doi: 10.1016/S2352-3026(19)30094-8. Epub 2019 Jun 12.

PMID:
31201085
4.

Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1.

Xu D, Claudiani S, Naresh K, Mucklow S, Neelakantan P, Yebra E, Apperley JF, Khorashad J, Milojkovic D.

Leuk Lymphoma. 2019 Jun 11:1-2. doi: 10.1080/10428194.2019.1622101. [Epub ahead of print] No abstract available.

PMID:
31184233
5.

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors.

Nteliopoulos G, Bazeos A, Claudiani S, Gerrard G, Curry E, Szydlo R, Alikian M, Foong HE, Nikolakopoulou Z, Loaiza S, Khorashad JS, Milojkovic D, Perrotti D, Gale RP, Foroni L, Apperley JF.

Haematologica. 2019 May 9. pii: haematol.2018.200220. doi: 10.3324/haematol.2018.200220. [Epub ahead of print]

6.

T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report.

Hanley B, Nesr G, Yebra-Fernandez E, Brown L, Rabitsch A, Killeen N, Claudiani S, Milojkovic D, Kanfer E, Apperley J, Naresh KN.

J Clin Pathol. 2019 Jul;72(7):511-512. doi: 10.1136/jclinpath-2019-205799. Epub 2019 Apr 19. No abstract available.

PMID:
31004076
7.

Patient-reported outcomes in the phase 3 BFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Crescenzo R, Mamolo C, Reisman A, Hochhaus A, Brümmendorf TH; BFORE Study Investigators.

J Cancer Res Clin Oncol. 2019 Jun;145(6):1589-1599. doi: 10.1007/s00432-019-02894-3. Epub 2019 Apr 15.

PMID:
30989330
8.

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia.

Claudiani S, Gatenby A, Szydlo R, Nesr G, Shacham Abulafia A, Palanikawandar R, Nteliopoulos G, Khorashad J, Foroni L, Apperley JF, Milojkovic D.

Haematologica. 2019 Mar 28. pii: haematol.2018.214809. doi: 10.3324/haematol.2018.214809. [Epub ahead of print]

9.

Mesenchymal stromal cells for acute graft-versus-host disease: response at 1 week predicts probability of survival.

Galleu A, Milojkovic D, Deplano S, Szydlo R, Loaiza S, Wynn R, Marks DI, Richardson D, Orchard K, Kanfer E, Tholouli E, Saif M, Sivaprakasam P, Lawson S, Bloor A, Pagliuca A, Potter V, Mehra V, Snowden JA, Vora A, Kishore B, Hunter H, Apperley JF, Dazzi F.

Br J Haematol. 2019 Apr;185(1):89-92. doi: 10.1111/bjh.15749. Epub 2019 Jan 13.

10.

Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.

García-Gutiérrez V, Milojkovic D, Hernandez-Boluda JC, Claudiani S, Martin Mateos ML, Casado-Montero LF, González G, Jimenez-Velasco A, Boque C, Martinez-Trillos A, Vázquez IM, Payer ÁR, Senín A, Amustio Díez E, García AB, Carrascosa GB, Ortí G, Ruiz BC, Fernández MÁ, Del Carmen García Garay M, Giraldo P, Guinea JM, De Las Heras Rodríguez N, Hernán N, Pérez AI, Piris-Villaespesa M, Lorenzo JLL, Martí-Tutusaus JMM, Vallansot RO, Ortega Rivas F, Puerta JM, Ramirez MJ, Romero E, Romo A, Rosell A, Saavedra SS, Sebrango A, Tallon J, Valencia S, Portero A, Steegmann JL; Grupo Español de Leucemia Mieloide Crónica (GELMC).

Ann Hematol. 2019 Feb;98(2):321-330. doi: 10.1007/s00277-018-3507-2. Epub 2018 Nov 16.

PMID:
30446802
11.

Consensus on BCR-ABL1 reporting in chronic myeloid leukaemia in the UK.

Cross NCP, White HE, Evans PAS, Hancock J, Copland M, Milojkovic D, Mason J, Craine S, Mead AJ.

Br J Haematol. 2018 Sep;182(6):777-788. doi: 10.1111/bjh.15542. Epub 2018 Aug 20. Review.

12.

Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.

Beckerson J, Szydlo RM, Hickson M, Mactier CE, Innes AJ, Gabriel IH, Palanicawandar R, Kanfer EJ, Macdonald DH, Milojkovic D, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlu J.

Clin Nutr. 2019 Apr;38(2):738-744. doi: 10.1016/j.clnu.2018.03.008. Epub 2018 Mar 28.

13.

Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.

Müller MC, Cervantes F, Hjorth-Hansen H, Janssen JJWM, Milojkovic D, Rea D, Rosti G.

Crit Rev Oncol Hematol. 2017 Dec;120:52-59. doi: 10.1016/j.critrevonc.2017.10.002. Epub 2017 Oct 8. Review.

14.

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH.

J Clin Oncol. 2018 Jan 20;36(3):231-237. doi: 10.1200/JCO.2017.74.7162. Epub 2017 Nov 1.

15.

Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation.

Pavlů J, Auner HW, Szydlo RM, Sevillano B, Palani R, O'Boyle F, Chaidos A, Jakob C, Kanfer E, MacDonald D, Milojkovic D, Rahemtulla A, Bradshaw A, Olavarria E, Apperley JF, Pello OM.

Bone Marrow Transplant. 2017 Dec;52(12):1599-1601. doi: 10.1038/bmt.2017.113. Epub 2017 Jun 26.

16.

De-escalation of tyrosine kinase inhibitor dose in patients with chronic myeloid leukaemia with stable major molecular response (DESTINY): an interim analysis of a non-randomised, phase 2 trial.

Clark RE, Polydoros F, Apperley JF, Milojkovic D, Pocock C, Smith G, Byrne JL, de Lavallade H, O'Brien SG, Coffey T, Foroni L, Copland M.

Lancet Haematol. 2017 Jul;4(7):e310-e316. doi: 10.1016/S2352-3026(17)30066-2. Epub 2017 May 26.

17.

E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy.

Claudiani S, Apperley JF, Gale RP, Clark R, Szydlo R, Deplano S, Palanicawandar R, Khorashad J, Foroni L, Milojkovic D.

Haematologica. 2017 Aug;102(8):e297-e299. doi: 10.3324/haematol.2017.168740. Epub 2017 May 11. No abstract available.

18.

C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early- and long-term mortality.

Patel A, Szydlo RM, Auner HW, Kanfer EJ, MacDonald DH, Milojkovic D, Altaf S, Innes A, Gabriel I, Rahemtulla A, Chaidos A, Karadimitris A, Olavarria E, Apperley JF, Pavlů J.

Br J Haematol. 2018 Mar;180(6):889-892. doi: 10.1111/bjh.14454. Epub 2016 Nov 29. No abstract available.

19.

Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia.

Claudiani S, Apperley JF, Deplano S, Khorashad J, Foroni L, Palanicawandar R, Perry R, Milojkovic D.

Am J Hematol. 2016 Nov;91(11):E480-E481. doi: 10.1002/ajh.24495. Epub 2016 Sep 3. No abstract available.

20.

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia.

Steegmann JL, Baccarani M, Breccia M, Casado LF, García-Gutiérrez V, Hochhaus A, Kim DW, Kim TD, Khoury HJ, Le Coutre P, Mayer J, Milojkovic D, Porkka K, Rea D, Rosti G, Saussele S, Hehlmann R, Clark RE.

Leukemia. 2016 Aug;30(8):1648-71. doi: 10.1038/leu.2016.104. Epub 2016 Apr 28. Review.

21.

Next-Generation Sequencing-Assisted DNA-Based Digital PCR for a Personalized Approach to the Detection and Quantification of Residual Disease in Chronic Myeloid Leukemia Patients.

Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J, Huggett JF, Foroni L, Reid AG.

J Mol Diagn. 2016 Mar;18(2):176-89. doi: 10.1016/j.jmoldx.2015.09.005. Epub 2016 Feb 5.

22.

Allogeneic transplantation for CML in the TKI era: striking the right balance.

Innes AJ, Milojkovic D, Apperley JF.

Nat Rev Clin Oncol. 2016 Feb;13(2):79-91. doi: 10.1038/nrclinonc.2015.193. Epub 2015 Nov 17. Review.

23.

Hypereosinophilic syndrome: an indolent rash with a serious cardiac complication.

Merika EE, Lefroy D, Milojkovic D, Wakelin SH.

Clin Exp Dermatol. 2016 Mar;41(2):170-4. doi: 10.1111/ced.12709. Epub 2015 Jul 26. Review.

PMID:
26213289
24.

Neutrophilic leukemoid reaction in multiple myeloma.

Milojkovic D, Hunter A, Barton L, Cross NC, Bain BJ.

Am J Hematol. 2015 Nov;90(11):1090. doi: 10.1002/ajh.24106. No abstract available.

25.

Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial.

Mead AJ, Milojkovic D, Knapper S, Garg M, Chacko J, Farquharson M, Yin J, Ali S, Clark RE, Andrews C, Dawson MK, Harrison C.

Br J Haematol. 2015 Jul;170(1):29-39. doi: 10.1111/bjh.13379. Epub 2015 Mar 30.

PMID:
25824940
26.

Managing pregnancy in chronic myeloid leukaemia.

Palani R, Milojkovic D, Apperley JF.

Ann Hematol. 2015 Apr;94 Suppl 2:S167-76. doi: 10.1007/s00277-015-2317-z. Epub 2015 Mar 27. Review.

PMID:
25814083
27.

Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?

Radujkovic A, Guglielmi C, Bergantini S, Iacobelli S, van Biezen A, Milojkovic D, Gratwohl A, Schattenberg AV, Verdonck LF, Niederwieser DW, de Witte T, Kröger N, Olavarria E; Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Biol Blood Marrow Transplant. 2015 Jul;21(7):1230-6. doi: 10.1016/j.bbmt.2015.03.012. Epub 2015 Mar 19.

28.

Thyroid function abnormalities associated with ponatinib therapy in patients with chronic myeloid leukemia.

Palani R, Apperley JF, Reid A, Foroni L, Deplano S, Milojkovic D.

Thyroid. 2015 Jun;25(6):706-7. doi: 10.1089/thy.2014.0514. Epub 2015 Apr 28. No abstract available.

PMID:
25778107
29.

How I treat leukemia during pregnancy.

Milojkovic D, Apperley JF.

Blood. 2014 Feb 13;123(7):974-84. doi: 10.1182/blood-2013-08-283580. Epub 2013 Nov 22.

30.

Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects.

Neelakantan P, Rezvani K, May P, Gerrard G, Marco B, Paliompeis C, Reid A, Goldman J, Marin D, Milojkovic D.

Br J Haematol. 2014 Feb;164(4):608-10. doi: 10.1111/bjh.12648. Epub 2013 Nov 13. No abstract available.

PMID:
24219400
31.

Systemic mastocytosis - the importance of looking within bone marrow fragments: AJH Educational Material.

Bain BJ, Khoder A, Milojkovic D, Bernard T.

Am J Hematol. 2014 Jan;89(1):109-10. doi: 10.1002/ajh.23603. No abstract available.

32.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L.

Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.

PMID:
24117365
33.

PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.

Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti D.

J Clin Invest. 2013 Oct;123(10):4144-57. doi: 10.1172/JCI68951. Epub 2013 Sep 3.

34.

Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias.

Walker CJ, Oaks JJ, Santhanam R, Neviani P, Harb JG, Ferenchak G, Ellis JJ, Landesman Y, Eisfeld AK, Gabrail NY, Smith CL, Caligiuri MA, Hokland P, Roy DC, Reid A, Milojkovic D, Goldman JM, Apperley J, Garzon R, Marcucci G, Shacham S, Kauffman MG, Perrotti D.

Blood. 2013 Oct 24;122(17):3034-44. doi: 10.1182/blood-2013-04-495374. Epub 2013 Aug 22.

35.

Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies.

Oaks JJ, Santhanam R, Walker CJ, Roof S, Harb JG, Ferenchak G, Eisfeld AK, Van Brocklyn JR, Briesewitz R, Saddoughi SA, Nagata K, Bittman R, Caligiuri MA, Abdel-Wahab O, Levine R, Arlinghaus RB, Quintas-Cardama A, Goldman JM, Apperley J, Reid A, Milojkovic D, Ziolo MT, Marcucci G, Ogretmen B, Neviani P, Perrotti D.

Blood. 2013 Sep 12;122(11):1923-34. doi: 10.1182/blood-2013-03-492181. Epub 2013 Aug 7. Erratum in: Blood. 2014 May 8;123(19):3056.

36.

Progressive multifocal leukoencephalopathy associated with ruxolitinib.

Wathes R, Moule S, Milojkovic D.

N Engl J Med. 2013 Jul 11;369(2):197-8. doi: 10.1056/NEJMc1302135. No abstract available.

PMID:
23841743
37.

Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling.

de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, Mielke S, Bazeos A, Stringaris K, Ali S, Milojkovic D, Foroni L, Chaidos A, Cooper N, Gabriel I, Apperley J, Belsey S, Flanagan RJ, Goldman J, Shpall EJ, Kelleher P, Marin D, Rezvani K.

Blood. 2013 Jul 11;122(2):227-38. doi: 10.1182/blood-2012-11-465039. Epub 2013 May 29.

38.

Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT.

Innes AJ, Beattie R, Sergeant R, Damaj G, Foroni L, Marin D, Kanfer E, Mielke S, Milojkovic D, MacDonald D, Pavlu J, Rahemtulla A, Roberts I, Slade D, Bray E, Goldman J, Apperley J, Szydlo R, Dazzi F, Rezvani K.

Bone Marrow Transplant. 2013 Oct;48(10):1324-8. doi: 10.1038/bmt.2013.69. Epub 2013 May 20.

PMID:
23686098
39.

Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.

Auner HW, Szydlo R, Rone A, Chaidos A, Giles C, Kanfer E, Macdonald DH, Marin D, Milojkovic D, Pavlu J, Apperley JF, Rahemtulla A.

Leuk Lymphoma. 2013 Oct;54(10):2200-4. doi: 10.3109/10428194.2013.773998. Epub 2013 Mar 4.

PMID:
23387937
40.

Imatinib and chronic myeloid leukemia: close to the bone.

Terpos E, Apperley J, Milojkovic D.

Leuk Lymphoma. 2013 Aug;54(8):1581-2. doi: 10.3109/10428194.2013.772608. Epub 2013 Mar 27. No abstract available.

PMID:
23383598
41.

Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.

Neelakantan P, Gerrard G, Lucas C, Milojkovic D, May P, Wang L, Paliompeis C, Bua M, Reid A, Rezvani K, O'Brien S, Clark R, Goldman J, Marin D.

Blood. 2013 Apr 4;121(14):2739-42. doi: 10.1182/blood-2012-11-466037. Epub 2013 Feb 4.

42.

The next questions in chronic myeloid leukaemia and their answers.

Marin D, Rotolo A, Milojkovic D, Goldman J.

Curr Opin Hematol. 2013 Mar;20(2):163-8. doi: 10.1097/MOH.0b013e32835dd922. Review.

PMID:
23334193
43.

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy.

Aduwa E, Szydlo R, Marin D, Foroni L, Reid A, Goldman J, Apperley JF, Milojkovic D.

Blood. 2012 Dec 13;120(25):5087-8. doi: 10.1182/blood-2012-09-458463. No abstract available.

44.

MSQoL-54 predicts change in fatigue after inpatient rehabilitation for people with multiple sclerosis.

Drulovic J, Bursac LO, Milojkovic D, Tepavcevic DK, Gazibara T, Pekmezovic T.

Disabil Rehabil. 2013 Mar;35(5):362-6. doi: 10.3109/09638288.2012.704122. Epub 2012 Aug 16.

PMID:
22897503
45.

Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.

Ali S, Sergeant R, O'Brien SG, Foroni L, Hedgley C, Gerrard G, Milojkovic D, Stringaris K, Khoder A, Alsuliman A, Gilleece M, Gabriel IH, Cooper N, Goldman JM, Apperley JF, Clark RE, Marin D, Rezvani K.

Blood. 2012 Jul 19;120(3):697-8. doi: 10.1182/blood-2012-04-421016. No abstract available.

46.

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.

Marin D, Hedgley C, Clark RE, Apperley J, Foroni L, Milojkovic D, Pocock C, Goldman JM, O'Brien S.

Blood. 2012 Jul 12;120(2):291-4. doi: 10.1182/blood-2012-01-407486. Epub 2012 May 29.

47.

Platelet dysfunction associated with ponatinib, a new pan BCR-ABL inhibitor with efficacy for chronic myeloid leukemia resistant to multiple tyrosine kinase inhibitor therapy.

Neelakantan P, Marin D, Laffan M, Goldman J, Apperley J, Milojkovic D.

Haematologica. 2012 Sep;97(9):1444. doi: 10.3324/haematol.2012.064618. Epub 2012 Apr 24. No abstract available.

48.

Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.

Chaidos A, Patterson S, Szydlo R, Chaudhry MS, Dazzi F, Kanfer E, McDonald D, Marin D, Milojkovic D, Pavlu J, Davis J, Rahemtulla A, Rezvani K, Goldman J, Roberts I, Apperley J, Karadimitris A.

Blood. 2012 May 24;119(21):5030-6. doi: 10.1182/blood-2011-11-389304. Epub 2012 Feb 27.

49.

BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.

Alikian M, Gerrard G, Subramanian PG, Mudge K, Foskett P, Khorashad JS, Lim AC, Marin D, Milojkovic D, Reid A, Rezvani K, Goldman J, Apperley J, Foroni L.

Am J Hematol. 2012 Mar;87(3):298-304. doi: 10.1002/ajh.22272. Epub 2012 Jan 9. Review.

50.

Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients.

Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, Bua M, Reid A, Rezvani K, Foroni L, Goldman J, Marin D.

Blood. 2012 Feb 23;119(8):1838-43. doi: 10.1182/blood-2011-10-383000. Epub 2011 Dec 14.

Supplemental Content

Loading ...
Support Center